Aastrom Biosciences, Inc. (ASTM) Cash Flow Statement

Click line-items for a historical chart and %

Net loss
Depreciation and amortization	1.39M
Loss on property held for resale
Amortization of discounts and premiums on investments
Stock compensation expense	1.97M
Increase (decrease) in fair value of warrants
Inventory write downs and reserves
Stock issued pursuant to license agreement
Provision for losses on accounts receivable
Receivables	3.05M
Inventories	-2.33M
Other current assets	-278K
Accounts payable and accrued expenses	-2.17M
Accrued employee benefits	-205K
Net cash used for operating activities
Organizational costs
Purchase of short-term investments
Maturities of short-term investments
Property and equipment purchases
Proceeds from sale of property held for resale
Net cash used for investing activities
Net proceeds from issuance of preferred stock	469K
Net proceeds from issuance of common stock and warrants
Payments received for stock purchase rights and other, net
Restricted cash used as compensating balance
Proceeds from long-term debt
Principal payments under long-term debt obligations
Other, net
Net cash provided by (used for) financing activities
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period

Entities mentioned with ASTM

View All Entities